Maze Therapeutics, Inc. (MAZE) News
Follow Maze Therapeutics, Inc. (MAZE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Maze Therapeutics Price Target Maintained With a $110.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 11:41 AM UTC
L
Maze Therapeutics Initiated at Buy by Citigroup
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 03:15 PM UTC
L
Maze Therapeutics Price Target Maintained With a $48.00/Share by Wedbush
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 12:27 PM UTC
L
Wedbush reiterates Outperform rating on Maze Therapeutics, $48 price target
Wedbush reiterated their Outperform rating on Maze Therapeutics's stock with a price target of $48.00.The price target implies an upside of 69.1% from the Sep 22 close of $28.38.Key takeaways from the analyst notePositiv
EQUITY | Sep 23, 2026, 12:17 PM UTC
M
Maze shares jump after Vertex kidney drug study results
Maze Therapeutics shares rose after Vertex reported positive study results for its kidney disease drug, implying strong commercial potential for genetic kidney disease treatments.
EQUITY | Sep 22, 2026, 04:48 PM UTC
H
On Holding, Viking Therapeutics, Shopify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 1% on Monday. Shares of On Holding AG (NYSE: ONON ) rose sharply after the company affirmed its FY26 sales guidance above estimates and issued third-quarter
LIVE | Sep 22, 2026, 02:25 PM UTC
L
MAZE: HORIZON phase II data for AMKD shows strong efficacy, with pivotal trials and PKU advances ahead
Three clinical programs are advancing, with key HORIZON phase II data for AMKD expected soon and a pivotal trial planned. Initial results show strong efficacy across patient subgroups, and biomarker strategies are being
NEWS | Sep 15, 2026, 02:36 PM UTC
L
MAZE: HORIZON phase II data shows strong efficacy in AMKD, with pivotal trials and biomarker strategies ahead
Multiple clinical programs are advancing, with key HORIZON phase II data for AMKD expected soon and pivotal trials planned. Early results show strong efficacy and broad patient inclusion, while biomarker strategies and r
NEWS | Sep 15, 2026, 01:54 PM UTC
L
MAZE: Promising phase II results in AMKD and PKU, with pivotal trials and key data readouts ahead
Three clinical programs are advancing, with MZE829 showing promising phase II results in AMKD and broad potential across patient subgroups. Key data readouts and trial initiations are expected over the next two years, su
EQUITY | Sep 09, 2026, 02:59 PM UTC
L
MAZE advances Phase II kidney, metabolic studies; cash runway into 2029
MAZE said three clinical programs are advancing, including MZE829 with promising phase II results in AMKD and MZE782 progressing in PKU and CKD. HORIZON study adjustments target balanced enrollment; cash runway extends i
EQUITY | Sep 09, 2026, 02:30 PM UTC
L
Maze CEO Jason V. Coloma sells shares worth about $593K
Maze Therapeutics CEO Jason V. Coloma reported sales of common stock to satisfy tax withholding on vested restricted stock units, executed at weighted average prices of $26.376, $27.1211 and $26.0133 per share.
EQUITY | Sep 04, 2026, 08:31 PM UTC
L
MAZE - Maze Therapeutics to Participate in Three Upcoming Investor Conferences
MAZE - Maze Therapeutics to Participate in Three Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 11:01 AM UTC
L
Maze Therapeutics appoints new members to its board of directors
Maze Therapeutics announces appointments to its board of directors, according to TradeXchange Newsdesk, with no details on the individuals or effective timing provided in the feed.
REGULATION | Aug 13, 2026, 08:42 PM UTC
L
Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate
Maze Therapeutics (NASDAQ: MAZE ) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.73) by 4.11 percent. This is a 1.3 percent increase over losses of $(0.77) per share fro
EARNINGS | Aug 11, 2026, 08:36 PM UTC
L
MAZE - Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
MAZE - Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
EARNINGS | Aug 11, 2026, 08:01 PM UTC